Patents Assigned to Jiangsu Aosaikang Pharmaceutical Co., Ltd.
-
Publication number: 20240101655Abstract: The present disclosure relates to chimeric molecules which are fusion proteins comprising two components: an Ang-2 binding peptide linked to either a VEGF antibody or a VEGF receptor-Fc fusion protein. The Ang2 peptide, VEGF antibody, and VEGF receptor-Fc fusion proteins are each defined below with reference to percent identity to a reference sequence. The chimeric molecule is a fusion protein, dual antagonist of Ang2 and VEGF for treatment of cancers, proliferative retinopathies, neovascular glaucoma, macular edema, AMD, and rheumatoid arthritis.Type: ApplicationFiled: September 4, 2023Publication date: March 28, 2024Applicants: AskGene Pharma Inc., Jiangsu Aosaikang Pharmaceutical Co., Ltd.Inventors: Yuefeng Lu, Jian-Feng Lu
-
Publication number: 20230303714Abstract: Described and provided herein are novel antibodies for Claudin 18.2. Also described and provided are pharmaceutical compositions of the antibodies and methods of use for the treatment of cancer.Type: ApplicationFiled: November 21, 2022Publication date: September 28, 2023Applicants: AskGene Pharma Inc., Jiangsu AoSaiKang Pharmaceutical Co., Ltd.Inventors: Yuefeng Lu, Kurt Shanebeck, Lu Li, Lei Liu, Shiwen Zhang, Lan Yang, Jian-Feng Lu
-
Patent number: 11746147Abstract: The present disclosure relates to chimeric molecules which are fusion proteins comprising two components: an Ang-2 binding peptide linked to either a VEGF antibody or a VEGF receptor-Fc fusion protein. The Ang2 peptide, VEGF antibody, and VEGF receptor-Fc fusion proteins are each defined below with reference to percent identity to a reference sequence. The chimeric molecule is a fusion protein, dual antagonist of Ang2 and VEGF for treatment of cancers, proliferative retinopathies, neovascular glaucoma, macular edema, AMD, and rheumatoid arthritis.Type: GrantFiled: January 13, 2020Date of Patent: September 5, 2023Assignees: AskGene Pharma Inc., Jiangsu Aosaikang Pharmaceutical Co., Ltd.Inventors: Yuefeng Lu, Jian-Feng Lu
-
Patent number: 11505618Abstract: Described and provided herein are novel antibodies for Claudin 18.2. Also described and provided are pharmaceutical compositions of the antibodies and methods of use for the treatment of cancer.Type: GrantFiled: July 18, 2019Date of Patent: November 22, 2022Assignees: AskGene Pharma Inc., Jiangsu AoSaiKang Pharmaceutical Co., Ltd.Inventors: Yuefeng Lu, Kurt Shanebeck, Lu Li, Lei Liu, Shiwen Zhang, Lan Yang, Jian-Feng Lu
-
Patent number: 11345900Abstract: A monooxygenase having an amino acid sequence obtained by mutation of the amino acid sequence shown in SEQ ID NO:2 is disclosed. The use of the monooxygenase of the present invention in production of chiral sulfoxide-based drugs has advantages including mild reaction conditions, environmental friendliness, high yield, high optical purity of products, less peroxide products, and the like, and therefore the monooxygenase in the present invention has a good industrial application prospect in the production of proton pump inhibitors for the treatment of gastric ulcers.Type: GrantFiled: November 26, 2019Date of Patent: May 31, 2022Assignees: JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD., EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGYInventors: Yan Zhang, Huilei Yu, Shimiao Ren, Peng Zhao, Jianhe Xu, Yinqi Wu, Qian Zhao
-
Publication number: 20220002684Abstract: A monooxygenase having an amino acid sequence obtained by mutation of the amino acid sequence shown in SEQ ID NO:2 is disclosed. The use of the monooxygenase of the present invention in production of chiral sulfoxide-based drugs has advantages including mild reaction conditions, environmental friendliness, high yield, high optical purity of products, less peroxide products, and the like, and therefore the monooxygenase in the present invention has a good industrial application prospect in the production of proton pump inhibitors for the treatment of gastric ulcers.Type: ApplicationFiled: November 26, 2019Publication date: January 6, 2022Applicants: EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY, JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD.Inventors: Yan ZHANG, Huilei YU, Shimiao REN, Peng ZHAO, Jianhe XU, Yinqi WU, Qian ZHAO
-
Patent number: 11187683Abstract: A high performance liquid chromatography method used for dexrazoxane-related substances is provided, and in the method, a low-density bonding reversed-phase C18 chromatographic column resistant to pure water is employed; a gradient elution is carried out with mobile phase A and mobile phase B as eluents, the mobile phase A being a buffer, and the mobile phase B being an organic solvent; the volume percent of mobile phase A in eluents in a first stage of the gradient elution is not lower than 90%, and the duration of the first stage of the gradient elution ranges from 15˜30 minutes. By means of the analytical method, dexrazoxane is effectively separated from main impurities, and the qualities of the active pharmaceutical ingredients of dexrazoxane and the preparations thereof could be better controlled.Type: GrantFiled: November 30, 2017Date of Patent: November 30, 2021Assignee: JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD.Inventors: Xiangfeng Chen, Hongyu Chen, Shuaihua Tian, Min Sun, Changjun Fan
-
Patent number: 11078184Abstract: A dexrabeprazole sodium compound includes crystal forms B and C. The crystal form B has good stability and flowability. The crystal form C is an anhydrous crystal form and has good stability and low hygroscopicity. The crystal forms are suitable for preparing a dexrabeprazole sodium preparation.Type: GrantFiled: June 22, 2018Date of Patent: August 3, 2021Assignees: JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD., NANJING HAIRUN PHARMACEUTICAL CO., LTD.Inventors: Xiangfeng Chen, Hongyu Chen, Xiaoxin Li, Xun Pan, Min Sun
-
Patent number: 11001866Abstract: A strain of Burkholderia is Burkholderia glathei ECU0712, with an accession number of CGMCC NO. 14464. With the strain or its extract as the biocatalyst, thioether is catalyzed to be oxidized asymmetrically to chiral sulfoxide, with significant advantages that the obtained product has a high optical purity, and benefits of a simple reaction system, short preparation time of the catalyst and a high yield of the product.Type: GrantFiled: October 25, 2017Date of Patent: May 11, 2021Assignees: JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD., EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGYInventors: Huilei Yu, Qian Zhao, Yan Zhang, Jiang Pan, Jianhe Xu
-
Patent number: 10966993Abstract: An injectable pharmaceutical composition of a sulfonylurea drug and a preparation method thereof were described. The pharmaceutical composition contains a sulfonylurea drug, a cyclodextrin and an additive.Type: GrantFiled: December 13, 2017Date of Patent: April 6, 2021Assignee: JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD.Inventors: Wu Zhong, Chunsheng Gao, Wei Gong, Song Li, Hongyu Chen
-
Publication number: 20200385770Abstract: A strain of Burkholderia is Burkholderiaglathei ECU0712, with an accession number of CGMCC NO. 14464. With the strain or its extract as the biocatalyst, thioether is catalyzed to be oxidized asymmetrically to chiral sulfoxide, with significant advantages that the obtained product has a high optical purity, and benefits of a simple reaction system, short preparation time of the catalyst and a high yield of the product.Type: ApplicationFiled: October 25, 2017Publication date: December 10, 2020Applicants: JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD., EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGYInventors: Huilei YU, Qian ZHAO, Yan ZHANG, Jiang PAN, Jianhe XU
-
Patent number: 10787651Abstract: A Bradyrhizobium monooxygenase, a gene for encoding the monooxygenase, a recombinant expression vector comprising the gene and a recombinant transformant, a method of preparing the monooxygenase by the recombinant expression transformant, and a method of preparing an optically pure chiral sulfoxide by the monooxygenase, in particular to a method of preparing prazole drugs by means of catalyzing the asymmetric oxidation of thioether, a prazole precursor. As compared with other methods of preparing an optically pure sulfoxide, the product produced by the monooxygenase of the present invention as a catalyst has high optical purity, avoids the generation of the byproduct sulfone, and has advantages of mild reaction conditions, simple and convenient operations, easy amplification, etc.Type: GrantFiled: April 13, 2018Date of Patent: September 29, 2020Assignees: JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD., EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGYInventors: Huilei Yu, Yan Zhang, Jianhe Xu, Qian Zhao, Jiang Pan, Feng Liu, Guoqiang Lin
-
Patent number: 10752652Abstract: A method for preparing a ?-nucleoside compound, including the following steps: 1) performing a silylation reaction of a nitrogenous base or an analogue thereof in the presence of TMSOTf to give the nitrogenous base or the analogue thereof being protected by trimethylsilyl; 2) performing a direct glycosylation reaction of the reaction liquid, without being isolated, and a five- or six-membered ring saccharide or a derivative thereof closed by a hydroxyl protecting group to give a closed ?-nucleoside compound; and 3) performing a deprotection reaction to give the ?-nucleoside compound. The method uses a one-pot process to prepare the key intermediates of the ?-nucleoside compound, and the yield of materials in ?-configuration increases significantly. The method has the benefits of simple operations, being energy conservation and environment protection, and being suitable for industrial applications.Type: GrantFiled: December 21, 2017Date of Patent: August 25, 2020Assignee: JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD.Inventors: Zaiwei Zong, Qian Zhao, Ruifeng Yang, Gan Li, Chao Yi, Haixi Zhu
-
Publication number: 20200216414Abstract: A dexrabeprazole sodium compound includes crystal forms B and C. The crystal form B has good stability and flowability. The crystal form C is an anhydrous crystal form and has good stability and low hygroscopicity. The crystal forms are suitable for preparing a dexrabeprazole sodium preparation.Type: ApplicationFiled: June 22, 2018Publication date: July 9, 2020Applicants: JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD., NANJING HAIRUN PHARMACEUTICAL CO., LTD.Inventors: Xiangfeng CHEN, Hongyu CHEN, Xiaoxin LI, Xun PAN, Min SUN
-
Patent number: 10654922Abstract: The present disclosure relates to chimeric molecules which are fusion proteins comprising two components: an Ang-2 binding peptide linked to either a VEGF antibody or a VEGF receptor-Fc fusion protein. The Ang2 peptide, VEGF antibody, and VEGF receptor-Fc fusion proteins are each defined below with reference to percent identity to a reference sequence. The chimeric molecule is a fusion protein, dual antagonist of Ang2 and VEGF for treatment of cancers, proliferative retinopathies, neovascular glaucoma, macular edema, AMD, and rheumatoid arthritis.Type: GrantFiled: May 11, 2017Date of Patent: May 19, 2020Assignees: AskGene Pharma Inc., Jiangsu Aosaikang Pharmaceutical Co., Ltd.Inventors: Yuefeng Lu, Jian-Feng Lu
-
Publication number: 20200140830Abstract: A Bradyrhizobium monooxygenase, a gene for encoding the monooxygenase, a recombinant expression vector comprising the gene and a recombinant transformant, a method of preparing the monooxygenase by the recombinant expression transformant, and a method of preparing an optically pure chiral sulfoxide by the monooxygenase, in particular to a method of preparing prazole drugs by means of catalyzing the asymmetric oxidation of thioether, a prazole precursor. As compared with other methods of preparing an optically pure sulfoxide, the product produced by the monooxygenase of the present invention as a catalyst has high optical purity, avoids the generation of the byproduct sulfone, and has advantages of mild reaction conditions, simple and convenient operations, easy amplification, etc.Type: ApplicationFiled: April 13, 2018Publication date: May 7, 2020Applicants: JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD., EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGYInventors: Huilei YU, Yan ZHANG, Jianhe XU, Qian ZHAO, Jiang PAN, Feng LIU, Guoqiang LIN
-
Publication number: 20200131260Abstract: The present disclosure relates to chimeric molecules which are fusion proteins comprising two components: an Ang-2 binding peptide linked to either a VEGF antibody or a VEGF receptor-Fc fusion protein. The Ang2 peptide, VEGF antibody, and VEGF receptor-Fc fusion proteins are each defined below with reference to percent identity to a reference sequence. The chimeric molecule is a fusion protein, dual antagonist of Ang2 and VEGF for treatment of cancers, proliferative retinopathies, neovascular glaucoma, macular edema, AMD, and rheumatoid arthritis.Type: ApplicationFiled: January 13, 2020Publication date: April 30, 2020Applicants: AskGene Pharma Inc., Jiangsu Aosaikang Pharmaceutical Co., Ltd.Inventors: Yuefeng Lu, Jian-Feng Lu
-
Publication number: 20200040101Abstract: Described and provided herein are novel antibodies for Claudin 18.2. Also described and provided are pharmaceutical compositions of the antibodies and methods of use for the treatment of cancer.Type: ApplicationFiled: July 18, 2019Publication date: February 6, 2020Applicants: AskGene Pharma Inc., Jiangsu AoSaiKang Pharmaceutical Co., Ltd.Inventors: Yuefeng Lu, Kurt Shanebeck, Lu Li, Lei Liu, Shiwen Zhang, Lan Yang, Jian-Feng Lu
-
Publication number: 20200003737Abstract: A high performance liquid chromatography method used for dexrazoxane-related substances is provided, and in the method, a low-density bonding reversed-phase C18 chromatographic column resistant to pure water is employed; a gradient elution is carried out with mobile phase A and mobile phase B as eluents, the mobile phase A being a buffer, and the mobile phase B being an organic solvent; the volume percent of mobile phase A in eluents in a first stage of the gradient elution is not lower than 90%, and the duration of the first stage of the gradient elution ranges from 15˜30 minutes. By means of the analytical method, dexrazoxane is effectively separated from main impurities, and the qualities of the active pharmaceutical ingredients of dexrazoxane and the preparations thereof could be better controlled.Type: ApplicationFiled: November 30, 2017Publication date: January 2, 2020Applicant: JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD.Inventors: Xiangfeng CHEN, Hongyu CHEN, Shuaihua TIAN, Min SUN, Changjun FAN
-
Publication number: 20190345189Abstract: A method for preparing a ?-nucleoside compound, including the following steps: 1) performing a silylation reaction of a nitrogenous base or an analogue thereof in the presence of TMSOTf to give the nitrogenous base or the analogue thereof being protected by trimethylsilyl; 2) performing a direct glycosylation reaction of the reaction liquid, without being isolated, and a five- or six-membered ring saccharide or a derivative thereof closed by a hydroxyl protecting group to give a closed ?-nucleoside compound; and 3) performing a deprotection reaction to give the ?-nucleoside compound. The method uses a one-pot process to prepare the key intermediates of the ?-nucleoside compound, and the yield of materials in ?-configuration increases significantly. The method has the benefits of simple operations, being energy conservation and environment protection, and being suitable for industrial applications.Type: ApplicationFiled: December 21, 2017Publication date: November 14, 2019Applicant: JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD.Inventors: Zaiwei ZONG, Qian ZHAO, Ruifeng YANG, Gan LI, Chao YI, Haixi ZHU